Response to Maccio et al, "Multifactorial pathogenesis of COVID-19-related coagulopathy: Can defibrotide have a role in the early phases of coagulation disorders?"

Affiliations

• ¹ Frank H. Netter M.D. School of Medicine at Quinnipiac University, North Haven, CT, USA.
• ² Department of Surgery, Yale University School of Medicine, New Haven, CT, USA.
• ³ Department of Oncology and Hematology, Humanitas Clinical and Research Center - IRCCS, Rozzano-Milano, Italy.
• ⁴ Department of Biomedical Sciences, Humanitas University, Rozzano-Milano, Italy.
• ⁵ Intensive Care Unit, Virgen de la Arrixaca University Hospital, University of Murcia, Murcia, Spain.
• ⁶ Technion Integrated Cancer Center, Rappaport Faculty of Medicine, Technion, Haifa, Israel.
• ⁷ Techitra s.r.l., Milan, Italy.
• ⁸ Department of Molecular Pharmacology and Therapeutics, Hemostasis and Thrombosis Research Laboratories, Loyola University Medical Center, Chicago, IL, USA.
• ⁹ Department of Hematologic Oncology, Dana Farber Cancer Institute, Boston, MA, USA.
• ¹⁰ Mater University Hospital, UCD School of Medicine and Medical Science, Dublin, Ireland.
• ¹¹ Department of Pediatrics, Blood and Marrow Transplantation Program, University of Michigan, Ann Arbor, MI, USA.
• ¹² Department of Internal Medicine, Blood and Marrow Transplantation Program, University of Michigan, Ann Arbor, MI, USA.
• ¹³ Josep Carreras Leukaemia Research Institute, Hospital Clinic, University of Barcelona, Barcelona, Spain.
• ¹⁴ Barcelona Endothelium Team, Barcelona, Spain.
• ¹⁵ Hematopathology, Centre Diagnostic Biomedic, Hospital Clinic, Institut d'Investigacions Biomediques August Pi i Sunyer, Universitat de Barcelona, Barcelona, Spain.
• ¹⁶ Department of Hematology, Stem Cell Transplant and Cell Therapy Unit, IMIB-Arrixaca, Virgen de la Arrixaca University Hospital, University of Murcia, Murcia, Spain.